ArticleOncotarget
Eradicating cancer cells: struggle with a chameleon.
Article in Oncotarget. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.Frontiers in immunology · 2018Article
- Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer.World journal of gastroenterology · 2014Review
- Aiming to immune elimination of ovarian cancer stem cells.World journal of stem cells · 2013Review
- The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.Cellular oncology (Dordrecht, Netherlands) · 2013Article
- SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells.Oncogenesis · 2013Article
- High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.Oncotarget · 2012Article
- Review
- Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells.Oncotarget · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eradication of cancer stem cells to abrogate tumor growth is a new treatment modality. However, like normal cells cancer cells show plasticity. Differentiated tumor stem cells can acquire stem cell properties when they gain access to the stem cell niche. This indicates that eradicating of stem cells (emptying of the niche) alone will not lead to eradication of the tumor. Treatment should be directed to cancer stem cells and more mature cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.